Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Capitalistaon Nov 22, 2022 8:55am
141 Views
Post# 35118152

RE:RE:is it possible ?

RE:RE:is it possible ?Existing share price has nothing to do with buyout price.  The share price might skyrocket before a purchase, but only if there is a PR saying negotiations are taking place (unlikely) or credible rumours start circulating that buyout negotiations are underway.  Buyout speculation on the Stockhouse board does not count as a credible rumour. 

If an acceptable buyout offer is received, ONC's Board will likely authorize management to bring the proposed deal to shareholders for approval.  At that point, it is likely that a leak from an existing shareholder will cause the price will go up.  There may even be a PR introducing the buyout offer to the market but noting that shareholder approval has to be obtained. In these cases, the share price will skyrocket.

I doubt that ONC's Board would approve a buyout that is not in the billions given the revenue potential of pelareorep.
<< Previous
Bullboard Posts
Next >>